2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
11 May 2017
Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study
09 May 2017
Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017
04 May 2017
Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study
24 April 2017
Auris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency
31 March 2017
Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5
29 March 2017
Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results
14 March 2017
Auris Medical to Present at the 29th Annual Roth Conference on March 14
08 March 2017
Auris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14
07 March 2017
Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss
24 February 2017
Auris Medical and King's College London Extend Tinnitus Collaboration
22 February 2017
Auris Medical Announces Closing of $10 Million Public Offering
21 February 2017
Auris Medical Announces Pricing of $10 Million Public Offering
15 February 2017
Auris Medical Announces Proposed Public Offering of Common Shares and Warrants
14 February 2017
Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo
03 February 2017
Auris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow, February 3, 2017
02 February 2017
Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
26 January 2017